Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients

MeSH terms

• Adult
• Aged
• Aged, 80 and over
• Benzamides
• Dasatinib
• Dose-Response Relationship, Drug
• Drug Resistance, Neoplasm*
• Female
• Humans
• Imatinib Mesylate
• Italy
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
• Male
• Middle Aged
• Neoplasm, Residual / diagnosis
• Neoplasm, Residual / genetics
• Piperazines / pharmacokinetics
• Pyrimidines / administration & dosage*
• Pyrimidines / pharmacokinetics
• Pyrimidines / toxicity
• Remission Induction
• Retrospective Studies
• Survival Analysis
• Thiazoles / administration & dosage*
• Thiazoles / toxicity
• Treatment Outcome
• Young Adult